Solve Therapeutics

Solve Therapeutics acquires or in-licenses clinical-stage drug candidates — typically Phase I through Phase III — that large pharmaceutical companies have deprioritized for commercial reasons rather than efficacy or safety failures. It then redesigns clinical development plans around narrower indications or more efficient trial architectures. The value proposition is acquiring assets with existing human data at a discount to original development cost (per the firm's official communications).

Chairman Eckard Weber drives the firm's sourcing strategy and final asset-acquisition decisions. Weber has a track record spanning multiple biotech startups, including Payden&r, where he applied a similar capital-efficient model. The firm runs a lean operational team, with clinical and regulatory expertise brought in on a project basis tied to specific acquired assets.

The firm's capital structure is not publicly disclosed. It has not announced a traditional venture fundraise, institutional limited-partner backing, or a permanent capital vehicle. The operating model suggests either founder-anchored equity, single-family-office backing, or asset-level financing structures, but no source confirms any of these as of mid-2026.

A standard biotech startup identifies a biological target and builds a discovery engine around it, carrying substantial scientific risk. Solve Therapeutics skips discovery entirely by acquiring shelved but clinically validated compounds. The risk it carries is regulatory and executional — designing the right trial rather than proving the biology works for the first time. This compresses the timeline from acquisition to potential approval compared to new-entity discovery.

Oncology, immunology, and rare disease. The firm targets solid-tumor therapies and certain inflammatory-disease programs that have existing Phase I or Phase II data but fell outside the commercial threshold of the original sponsor's portfolio strategy (per the firm's official communications).